Table 4.
Adverse events
| Adverse event | Lidocaine | Hydromorphone | Difference (95% CI) |
|---|---|---|---|
| Any patient reported symptom | |||
| Yes | 23 (30%) | 28 (36%) | 6% (−8, 21%) |
| No | 54 (70%) | 49 (64%) | |
| Specific symptoms reported by patients | |||
| Dizziness | 4 (5%) | 14 (18%) | |
| Drowsiness | 6 (8%) | 4 (5%) | |
| Headache | 6 (8%) | 3 (4%) | |
| Nausea | 9 (12%) | 13 (17%) | |
| Pruritis | 1 (1%) | 2 (3%) | |
| Change in management due to investigational medication | |||
| Yes | 0 (0%) | 0 (0%) | |
| No | 77 (100%) | 77 (100%) | 0% |
| Unplanned return visit to ED within 1 week | |||
| Yes | 2 (3%) | 0 (0%) | 3% (−1, 6%) |
| No | 71 (97%) | 75 (100%) | |
| Missing | 4 | 2 | |
| Required naloxone | |||
| Yes | 0 (0%) | 0 (0%) | |
| No | 77 (100%) | 77 (100%) | 0% |